Alnylam Pharmace. buy TD Cowen
Start price
25.06.24
/
50%
€222.10
Target price
25.06.25
€263.30
Performance (%)
2.16%
Price
28.06.24
€226.90
Summary
This prediction is currently active. The BUY prediction by TD_Cowen shows slight gains of 2.16%. This prediction currently runs until 25.06.25. The prediction end date can be changed by TD_Cowen at any time. TD_Cowen has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Alnylam Pharmace. | 2.16% |
| iShares Core DAX® | 0.238% |
| iShares Nasdaq 100 | -0.304% |
| iShares Nikkei 225® | 2.271% |
| iShares S&P 500 | -0.296% |
Comments by TD_Cowen for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at TD Cowen from $260.00 to $282.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat